BIOLIFE SOLUTIONS INC (BLFS) Stock Price, Quote, News and Overview
NASDAQ:BLFS - Nasdaq - US09062W2044 - Common Stock - Currency: USD
BLFS Quote, Performance and Key Statistics
26.67
-0.84 (-3.05%)
The current stock price of BLFS is 26.67 USD. In the past month the price decreased by -4.2%. In the past year, price increased by 52.4%.
BLFS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
| DHR | DANAHER CORP | 28.07 | 151.18B | ||
| A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
| IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
| WAT | WATERS CORP | 31.58 | 22.26B | ||
| ICLR | ICON PLC | 14.39 | 16.63B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
| ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
| RVTY | REVVITY INC | 23.23 | 13.85B | ||
| AVTR | AVANTOR INC | 17.3 | 11.78B | ||
| TEM | TEMPUS AI INC | N/A | 10.72B |
Related stock screener links
About BLFS
Company Profile
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 409 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Company Info
BIOLIFE SOLUTIONS INC
Suite 310, 3303 Monte Villa Parkway
Bothell WASHINGTON 98021 US
CEO: Michael Rice
Employees: 412
Company Website: https://www.biolifesolutions.com/
Investor Relations: https://investors.biolifesolutions.com/
Phone: 14254011400
BIOLIFE SOLUTIONS INC / BLFS FAQ
What is the stock price of BIOLIFE SOLUTIONS INC today?
The current stock price of BLFS is 26.67 USD. The price decreased by -3.05% in the last trading session.
What is the ticker symbol for BIOLIFE SOLUTIONS INC stock?
The exchange symbol of BIOLIFE SOLUTIONS INC is BLFS and it is listed on the Nasdaq exchange.
On which exchange is BLFS stock listed?
BLFS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOLIFE SOLUTIONS INC stock?
16 analysts have analysed BLFS and the average price target is 31.52 USD. This implies a price increase of 18.18% is expected in the next year compared to the current price of 26.67. Check the BIOLIFE SOLUTIONS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOLIFE SOLUTIONS INC worth?
BIOLIFE SOLUTIONS INC (BLFS) has a market capitalization of 1.23B USD. This makes BLFS a Small Cap stock.
How many employees does BIOLIFE SOLUTIONS INC have?
BIOLIFE SOLUTIONS INC (BLFS) currently has 412 employees.
What are the support and resistance levels for BIOLIFE SOLUTIONS INC (BLFS) stock?
BIOLIFE SOLUTIONS INC (BLFS) has a support level at 26.49 and a resistance level at 26.7. Check the full technical report for a detailed analysis of BLFS support and resistance levels.
Is BIOLIFE SOLUTIONS INC (BLFS) expected to grow?
The Revenue of BIOLIFE SOLUTIONS INC (BLFS) is expected to decline by -25.59% in the next year. Check the estimates tab for more information on the BLFS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOLIFE SOLUTIONS INC (BLFS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BLFS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BLFS, evaluating the profitability, health, valuation and growth aspects
- BIOLIFE SOLUTIONS INC (BLFS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOLIFE SOLUTIONS INC (BLFS) Sales and EPS estimates to see what analysts future expectations are.
- BIOLIFE SOLUTIONS INC (BLFS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOLIFE SOLUTIONS INC (BLFS) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOLIFE SOLUTIONS INC (BLFS) Stock Chart to make your own analysis
- BIOLIFE SOLUTIONS INC (BLFS) Latest news and press-releases to stay up to date.
Does BIOLIFE SOLUTIONS INC (BLFS) stock pay dividends?
BLFS does not pay a dividend.
When does BIOLIFE SOLUTIONS INC (BLFS) report earnings?
BIOLIFE SOLUTIONS INC (BLFS) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of BIOLIFE SOLUTIONS INC (BLFS)?
BIOLIFE SOLUTIONS INC (BLFS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).
What is the Short Interest ratio of BIOLIFE SOLUTIONS INC (BLFS) stock?
The outstanding short interest for BIOLIFE SOLUTIONS INC (BLFS) is 7.21% of its float. Check the ownership tab for more information on the BLFS short interest.
BLFS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BLFS. When comparing the yearly performance of all stocks, BLFS is one of the better performing stocks in the market, outperforming 89.33% of all stocks.
BLFS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLFS. The financial health of BLFS is average, but there are quite some concerns on its profitability.
BLFS Financial Highlights
Over the last trailing twelve months BLFS reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 46.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.06% | ||
| ROE | -14.14% | ||
| Debt/Equity | 0.03 |
BLFS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to BLFS. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 29.49% and a revenue growth -25.59% for BLFS